

Remarks

Claims 13, 25, 26 and 30 have been cancelled.

Claims 17 and 21 have been amended.

Claims 13, 17, 21 and 26 are objected to because of the informality of reciting "decreasing" the formation of new tumor vessels. As helpfully suggested by the Examiner, Claims 17 and 21 have been amended to recite "inhibiting the formation" of new tumor vessels. Claims 13 and 26 have been cancelled. Accordingly, reconsideration and withdrawal of the objection are respectfully requested.

Claims 13, 21, 25, 26, 29 and 30 are rejected under 35 USC §112, first paragraph, as failing to comply with the enablement requirement. The rejection states that the specification enables a method of direct injection intratumorally or intramuscularly to a mammal comprising a melanoma or pulmonary metastasis thereof of an expression plasmid comprising a polynucleotide coding for a therapeutic peptide consisting of an amino acid with the sequence of SEQ ID NO: 2 wherein the polynucleotide is operably linked to an expression control sequence, followed by application of electric pulses to the site of the injection wherein expression of SEQ ID NO: 2 results in decrease in the number of intratumoral vessels. However, the rejection states that the specification does not enable one skilled in the art to make or use the claimed method commensurate in scope with the claims.

The Applicants note that Claim 21 has been amended to remove step a), and Claims 13, 25, 26 and 30 have been cancelled. Accordingly, the Applicants respectfully submit that the requirements of 35 USC §112 have been satisfied. Reconsideration and withdrawal of the rejection are respectfully requested.

In light of the foregoing, the Applicants respectfully submit that the entire application is now in condition for allowance, which is respectfully requested.

Respectfully submitted



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC/vbm
(215) 656-3381